This edition of the Life Science, Health & Wellness Technology Opportunity Engine (TOE) focuses on innovations that leverage AI and ML algorithms for diagnostics and drug discovery applications. A key focus of this issue is on predictive tests for cancers and other diseases. In particular, technologies which enable early diagnosis of cancers, support biomarker discovery and disease prognosis have been covered. Another focus of this issue is on predictive genetic tests, which offer a comprehensive picture of an individual’s risk of disease development, and also for wellness.
The Life Science, Health & Wellness TOE will feature disruptive technology advances in the global life sciences industry. The technologies and innovations profiled will encompass developments across genetic engineering, drug discovery and development, biomarkers, tissue engineering, synthetic biology, microbiome, disease management, as well as health and wellness among several other platforms.
The Health & Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare.
The Life Science, Health & Wellness TOE will feature disruptive technology advances in the global life sciences industry. The technologies and innovations profiled will encompass developments across genetic engineering, drug discovery and development, biomarkers, tissue engineering, synthetic biology, microbiome, disease management, as well as health and wellness among several other platforms.
The Health & Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare.
Table of Contents
1. Innovations in Life Sciences, Health & Wellness- Advanced Computational Platform for Protein Based Therapeutics Design
- Multiple Property Optimization in Protein Designing
- Proteinqure - Investor Dashboard
- Covalent Fragment-Based Drug Discovery for Precision Medicine
- Chemoproteomics Platform Unlocks Proteome to Scan for Undruggable Targets
- Frontier - Investor Dashboard
- Cost-Effective and Simple AI Based Novel Target Discovery Platform
- Delivering Comprehensive Biomaps for Protome Wide Screening
- Standigm - Investor Dashboard
- Artificial Intelligence (AI) Technology Identifying Disease Risk
- Precise Prediction of Disease Onset and Cause
- Prealize Health - Investor Dashboard
- Predictive Genetic Tests for the Early Detection of Genetic Diseases
- Myriad - Covering Multiple Cancers, Including Predictive Diagnostics and Suggested Treatments
- Myriad - Investor Dashboard
- Dna Tests for Hereditary Cancer Screening and Therapy
- Positive Bioscience - Creating Awareness of Genetic Tests in India
- Positive Bioscience - Investor Dashboard
- Direct to Consumer Tests for Personal Nutrition and Wellness
- 24Genetics - Partnerships with Local Dealers or Strategic Players to Distribute Tests
- 24Genetics - Investor Dashboard
- Comprehensive Genetic Diagnostics for Cancer
- Cegat - Leverages Both Single Gene and Gene Panel Analysis
- Cegat - Investor Dashboard
- Prevention of COVID-19 Transmissibility by Modified Antibody
- University of California's Technology Value Proposition
3. Legal Disclaimer
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- 24Genetics
- Cegat
- Frontier
- Myriad
- Positive Bioscience
- Prealize Health
- Proteinqure
- Standigm
